KRAS and cancer: Despite the activation of the p44/42 MAPK pathway by mutant KRAS, compensatory feedback activation has been reported to be associated with failure of MEK inhibitors as a monotherapy in clinical trials for the treatment of PDAC and other cancers harboring KRAS mutation [32, 54–56].